Incyte price target raised to $100 from $95 at Cowen

Cowen analyst Marc Frahm raised the firm’s price target on Incyte to $100 from $95 and keeps an Outperform rating on the shares. The analyst said they reported strong Opzelura revenue growth that was driven by strong volume and net pricing gains and given strong physician feedback, we expect these trends to continue